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Immunization of BALB/c mice with HIVBr18, a DNA vaccine containing 18 CD4+ T cell 
epitopes from human immunodeficiency virus (HIV), induced specific CD4+ and CD8+ 
T  cell responses in a broad, polyfunctional and persistent manner. With the aim of 
increasing the immunogenicity of this vaccine, the effect of Propionibacterium acnes as 
an adjuvant was evaluated. The adjuvant effects of this bacterium have been extensively 
demonstrated in both experimental and clinical settings. Herein, administration of two 
doses of HIVBr18, in the presence of P. acnes, increased the proliferation of HIV-1-
specific CD4+ and CD8+ T lymphocytes, the polyfunctional profile of CD4+ T cells, the 
production of IFN-γ, and the number of recognized vaccine-encoded peptides. One of 
the bacterial components responsible for most of the adjuvant effects observed was 
a soluble polysaccharide extracted from the P. acnes cell wall. Furthermore, within 
10 weeks after immunization, the proliferation of specific T cells and production of IFN-γ 
were maintained when the whole bacterium was administered, demonstrating a greater 
effect on the longevity of the immune response by P. acnes. Even with fewer immuni-
zation doses, P. acnes was found to be a potent adjuvant capable of potentiating the 
effects of the HIVBr18 vaccine. Therefore, P. acnes may be a potential adjuvant to aid 
this vaccine in inducing immunity or for therapeutic use.
Keywords: Propionibacterium acnes, adjuvant, human immunodeficiency virus-1, Dna vaccine, cD4+ T  cell, 
immunomodulation
inTrODUcTiOn
Human immunodeficiency virus (HIV) was discovered and characterized more than thirty years ago 
(1, 2), and the epidemic it causes is still a significant public health problem. Despite favorable changes 
in the incidence of HIV in many countries, data from the World Health Organization estimated that 
more than 36.7 million people worldwide were living with HIV, and 1.1 million lost their lives to 
acquired immune deficiency syndrome (AIDS) in 2015 (3).
Adaptive immunity against HIV-1 infection is mediated by specific CD4+ and CD8+ lympho-
cytes and by neutralizing and non-neutralizing antibodies (4, 5). The contribution of cytotoxic 
T  lymphocytes (CTLs) in the control of viremia has been demonstrated (6). However, although 
CTLs positively influence the progression of clinical diseases (7, 8), CTLs alone are not sufficient 
to control disease (9).
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CD4+ T  lymphocytes, whose mass destruction by infection 
facilitates the development of the main symptoms of AIDS, can 
also play a protective role. These cells assist the induction and 
maintenance of CTL responses, the differentiation of B lympho-
cytes into plasma cells, and the expansion of memory B  cells 
(10–12). Proliferation of HIV-1-specific CD4+ T  lymphocytes 
has been shown to be related to decreased viremia by controlling 
HIV-1 replication (13), and polyfunctional activity of these cells 
in the mucosal region, as well as the presence of HIV-specific 
cytotoxic CD4+ T lymphocytes, may be beneficial during HIV-1 
progression (14–18). Moreover, depletion of CD4+ T  cells has 
been shown to result in reduced protection against SIV chal-
lenge in SIV-vaccinated non-human primates (19). Due to the 
importance of the cellular immune response against HIV-1 infec-
tion, the development of vaccine candidates targeting conserved 
T  lymphocyte epitopes, especially of CD4+ T cells, has become 
relevant (20, 21).
In previous reports, our group scanned the entire consensus 
proteome of HIV-1 subtype B with an algorithm called TEPITOPE, 
and we mapped 18 HIV-1-specific CD4+ T cell epitopes that were 
able to promiscuously bind to different HLA molecules (DR, DQ, 
and DP) (22). Peripheral blood mononuclear cells from more 
than 90% of evaluated HIV patients were able to recognize these 
peptides. Following this analysis, DNA vaccine HIVBr18, encod-
ing such epitopes, was produced (23, 24). Immunization of mice 
transgenic for common HLA class II molecules with HIVBr18 
led to extensive CD4+ and CD8+ T  lymphocyte responses that 
targeted 16 of 18 encoded epitopes and exhibited a persistent and 
polyfunctional profile (23). These studies suggested that such a 
vaccine could have broad coverage in the human population that 
could in turn recognize multiple HIV-1 peptides.
DNA vaccines have several advantages over recombinant viral 
vaccines, including being easier to access and cheaper to prepare 
and having a quicker mode of deployment in case of an emerging 
infection epidemic. However, the suboptimal immunogenicity of 
DNA vaccines in humans is a significant drawback and is probably 
due to inefficient transfection (25). Several approaches have been 
used to enhance their immunogenicity and enable efficient use 
in humans (26–28). Indeed, an ideal adjuvant for DNA vaccines 
should be capable of improving DNA uptake, gene expression, 
antigen processing and presentation and of modulating both the 
innate and adaptive immune responses. Some adjuvants are cur-
rently being used in clinical trials involving combined use with 
DNA vaccines, such as glucopyranosyl lipid adjuvant-aqueous 
formulation (29).
Propionibacterium acnes is a Gram-positive anaerobic bacillus 
that belongs to the normal cutaneous microbiota (30) and has 
beneficial immunomodulatory activity when used as a heat- or 
phenol-killed suspension. Since it is extensively used as an 
adjuvant in clinical trials, P. acnes can be a suitable candidate 
for vaccine approaches in humans (31, 32). Among its main 
biological activities, P. acnes promotes macrophage activation 
(33, 34), exhibits tumoricidal activity (34–39) and induces an 
adjuvant effect on antibody responses (40, 41), which altogether 
seem to explain the increase in pathogen resistance observed after 
intraperitoneal or subcutaneous treatment with this bacterium 
(42–47). The mechanisms responsible for the modulating effects 
of P. acnes on both innate and acquired immunity are mediated 
by proinflammatory cytokines, which are induced by treatment 
with this adjuvant in a manner dependent on TLR2, TLR9, and 
MyD88 (48–51). Due to this cytokine pattern, the killed P. acnes 
suspension has been used as a Th1 response inducer (52–54).
To investigate which component from P. acnes is related to the 
effects observed with the whole bacterium treatment, a cell wall 
polysaccharide (PS) purified from this bacterium was character-
ized by our group (55), and in different models, PS was shown 
to induce similar effects as those generated by the total bacterial 
suspension. The heat-killed P. acnes suspension and PS were both 
able to enhance an antibody response to a Trypanosoma cruzi 
DNA vaccine in mice (41), increase the number and tumoricidal 
activity of peritoneal macrophages (38), and enhance the number 
and maturation of dendritic cells (DCs) (56). Furthermore, we 
revealed that P. acnes and PS could not only direct a typical Th1 
response but also enhance the elicited Th2 pattern in a murine 
model of type I hypersensitivity reaction (55, 57). Thus, these 
findings indicate that PS may be one of the leading P. acnes 
components related to its beneficial effects.
The adjuvant effect of P. acnes on these experimental models 
has led to the conclusion that its modulation of the immune 
response probably occurs by direct action on antigen-presenting 
cells (APCs) (58). Indeed, the effect of P. acnes in recruiting 
and maturing DCs (52, 56) and its immunomodulation of the 
activation status of APCs, such as B lymphocytes, macrophages 
and DCs, which are responsible for T cell direction, have been 
previously demonstrated (58).
As P. acnes has been previously shown to increase the immu-
nogenicity of a DNA vaccine against T. cruzi in mice (41), herein, 
we investigated whether its association could also improve the 
immunogenicity of HIVBr18 immunization in BALB/c animals. 
Moreover, we examined whether PS could be related to one of 
the mechanisms by which P. acnes may function when associated 
with this vaccine. Due to its approved use in humans, previous 
use in clinical trials and commercial use in immunotherapy 
for immunosuppressed patients, P. acnes may be a promising 
adjuvant for increasing the immunogenicity of the DNA vaccine 
HIVBr18 in humans.
In addition, other adjuvants, such as bupivacaine (59) and a 
plasmid encoding GM-CSF (60), have also been simultaneously 
used with HIVBr18 in experimental models. However, although 
both induced some adjuvant effect, neither bupivacaine nor 
GM-CSF produced the immunomodulatory effect elicited by 
P. acnes, namely, increasing the magnitude and amplifying the 
recognition of HIVBr18 epitopes.
MaTerials anD MeThODs
animals
Eight-week-old female BALB/c mice (H-2d) were housed and 
handled under specific pathogen-free conditions at the animal 
care facilities of the Immunology Division of Federal University 
of São Paulo. Animal handling was conducted in strict compli-
ance with the National Institutes of Health Guide for the Care 
Use of Laboratory Animals and the Brazilian National Law 
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(11.794/2008). This study was approved by the Institutional 
Animal Care and Use Committee of the Federal University of São 
Paulo (permit number 4836281114).
adjuvants
Heat-Killed P. acnes Suspension
Propionibacterium acnes strain was obtained from Adolfo Lutz 
Institute, SP, Brazil. After three days in culture using anaerobic 
medium (Hemobac, Probac, SP, Brazil) at 37°C, bacteria were 
washed three times at 2,000 g for 30 min and then resuspended 
in saline. The bacterial suspension was autoclaved at 120°C for 
20  min, and protein concentration was determined using the 
Bradford method (61) and was then used to establish individual 
doses for immunization.
P. acnes Soluble PS Fraction
Polysaccharide was obtained by phenol-extraction and ethanol 
precipitation, as previously described by our group (55) and 
based on Palmer and Gerlough protocol for PS extraction (62). 
The Bradford method (61) was used to confirm PS purity with 
the absence of proteins, and the carbohydrate concentration was 
determined using the Dubois method (63).
Dna Vaccine
The DNA vaccine HIVBr18, which was previously described 
(23, 24), was used in this study. This construct was designed to 
encode sequences for 18 CD4+ epitopes derived from HIV-1 sub-
type B consensus sequence (22): gag1 to gag4, pol1 to pol3, env1 
to env5, rev, vpr2 and vpr3, vif2, vpu, and nef. Large-scale purifi-
cations of the empty vector pVAX1 and pVAX-HIVBr18 plasmid 
were performed using an EndoFree Plasmid Giga Kit (Qiagen) 
according to the manufacturer’s instructions. The obtained DNA 
was evaluated for yield and purity by spectrophotometry at 
260 nm and by endonuclease digestion with HindIII and XhoI.
Peptides
The 18 epitopes encoded by the DNA vaccine HIVBr18 were 
synthesized by solid-phase technology with amidation of the 
C-terminal carboxyl group (Biomatik). Peptide purity was 
defined as above 90%.
immunization schedule
Six mice per group were intramuscularly injected with two doses 
of 100  µg of plasmid pVAX-HIVBr18 or empty vector pVAX1 
per dose (1 µg/µl, in saline) and 50 µg for each quadriceps. Doses 
were administered at an interval of 2 weeks, and each dose was 
mixed with adjuvants (70 µg of protein of the heat-killed P. acnes 
suspension or 25 µg of PS) or with 0.9% saline. Mice were eutha-
nized, and splenocytes were collected 2 or 10 weeks after the last 
immunization. Experiments were repeated up to three times.
cell isolation for immune assays
Single-cell suspensions of splenocytes from the immunized 
groups were obtained 2 or 10 weeks after the last immunization 
by pooling samples from the animals in each group; however, for 
the cytotoxicity assay, each animal was individually analyzed. 
R10 medium (RPMI-1640 supplemented with 10% fetal bovine 
serum, 2 mM l-glutamine, 1 mM sodium pyruvate, 1% vitamin 
solution, 1% nonessential amino acids, penicillin/streptomycin, 
28  mM HEPES, 23.8  mM sodium bicarbonate, and 55  mM 
2-mercaptoethanol, Gibco) was used to resuspend cells, and cell 
viability was determined using trypan blue (Gibco).
iFn-γ elispot assay
After in vitro stimulation of splenocytes from immunized mice 
(5 × 105 cells/well) with 5 µM of 18 HIV-1 peptides (either pooled 
or individual), an ELISpot assay was performed using a mouse 
IFN-γ ELISpot Ready-SET-Go! Kit (eBioscience) according to 
the manufacturer’s instructions. Expression of spot-forming 
units (SFU/106 cells) was used to refer to the number of antigen-
specific T  lymphocytes and was calculated after subtracting 
values obtained for the unstimulated condition, and 15 SFU/106 
cells was considered as a cutoff.
cytometric Bead array
Splenocytes from immunized mice were cultured (1 × 106 cells/
well) with 5 µM of pooled HIV-1 peptides for five days under an 
atmosphere of 5% CO2 at 37°C. Supernatants were harvested, and 
cytokines were detected using a Mouse Th1/Th2/Th17 Cytometric 
Bead Array Kit (BD) according to the manufacturer’s instruction.
Proliferation assay
To assess whether T lymphocytes from immunized animals pro-
liferated in response to HIV-1-specific antigen, spleen cells were 
stained with 1.25  µM of carboxyfluorescein succinimidyl ester 
(CFSE) and cultured (triplicates of 5 × 105 cells/well) with 5 µM 
of pool of HIV-1 peptides or medium (R10) alone for five days 
under an atmosphere of 5% CO2 at 37°C. Cells were then collected 
and labeled for 30  min at 4°C with CD3 PE (145-2C11), CD4 
PerCP (RM4-5), and CD8 APC (53-6.7) antimouse monoclonal 
antibodies (BD) for proliferation evaluation. After washing, 
samples were analyzed using a FACSCanto™ II (BD) with appro-
priate compensation controls (single stained beads, CompBeads 
(BD), or CFSE-single stained cells). The frequency of proliferating 
T  lymphocyte subpopulations (CFSElow) among CD4+ CD3+ or 
CD8+ CD3+ cells (Figure S1 in Supplementary Material) was 
determined using FlowJo software, version 9.7.6 (Tree Star). 
The HIV-specific population was determined by estimating the 
number of CFSElow cells after HIV-1-specific stimulus and after 
subtracting values obtained for the unstimulated condition.
Detection of intracellular cytokine 
Production
To evaluate cytokine production from proliferating cells, spleen 
cells from immunized animals were stained with CFSE and 
cultured with 5  µM of the pool of HIV-1 peptides or medium 
(R10) alone as described above. However, for the last 12 h, cells 
were restimulated with the same antigen, 2 µg/mL of anti-CD28 
(eBioscience) and Brefeldin A-GolgiPlug™ (BD). In the end, cells 
were collected and labeled with CD3 APC-Cy7 (145-2C11), CD4 
PerCP (RM4-5), and CD8 Pacific Blue (53-6.7) antimouse mono-
clonal antibodies (BD) for 30 min at 4°C. Cells were then fixed 
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and permeabilized using a Cytofix/Cytoperm™ kit (BD) and then 
labeled with IL-2 PE (JES6-5H4), TNF-α PE-Cy7 (MP6-XT22) 
and IFN-γ APC (XMG1.2) antimouse monoclonal antibodies 
(BD) for 30 min at 4°C. After washing, samples were analyzed 
using a FACSCanto™ II (BD). The frequency of proliferating 
T cells that also produced each of the cytokines were determined 
by FlowJo software (Figure S1 in Supplementary Material). In 
addition, a Boolean gating platform was used to create all possible 
combinations of cytokine-producing cells.
cytotoxicity assay
Two groups of three to five mice were immunized with two 
doses of DNA HIVBr18 as described above, such that one group 
received no adjuvant, while the other received 70 µg of P. acnes at 
the first dose only. Two weeks after the last immunization, the cell 
line RAW 264.7 (mouse leukemic monocyte macrophage) was 
cultured in six-well plates (3 ×  105 cells/well) under an atmos-
phere of 5% CO2 at 37°C and maintained in R10 for 24 h. After 
this period, the cells were transfected with 2 µL of FuGENE® HD 
Transfection Reagent (Promega) and 3 µg of pVAX-HIVBr18 or 
3 µg of empty vector pVAX1 in Macrophage Medium (Gibco). 
After a 6-h incubation, R10 without antibiotic was added to each 
well. The next day, the culture medium was changed to R10 with 
[methyl-3H] thymidine (5 μCi/mL, Amersham Biosciences). After 
24 h, transfected RAW 264.7 cells were collected after dissociation 
with 1% PBS-EDTA, and cellular concentration and viability were 
determined using trypan blue. Then, 1 × 104 of both transfected 
cells were cocultured with splenocytes from immunized mice at a 
1:50 ratio of target to effector cells in 96-well round bottom plates 
to detect cytotoxicity (E) against target cells expressing or not 
expressing the HIV-1 antigen (transfected cells). Cells were incu-
bated for 3.5 h under an atmosphere of 5% CO2 at 37°C and were 
then collected using a cell harvester (PerkinElmer). A β-counter 
(MicroBeta2 LumiJET—PerkinElmer) was used to measure 
radioactivity in counts per minute (CPM). Spontaneous lysis (S) 
was determined by culturing transfected cells alone in R10. The 
lysis percentage was calculated using the following equation:
 % /Lysis Scpm Ecpm Scpm 100.= −( ) ×  
The specific lysis percentage was determined by subtracting 
the lysis value obtained when the target cell was transfected with 
pVAX-HIVBr18 (specific) from the lysis value obtained when the 
target cell was transfected with empty pVAX1 (unspecific).
Data analysis
Significant differences between vaccinated groups were calculated 
by one-way analysis of variance followed by Tukey’s Multiple 
Comparison Test using GraphPad Prism software.
resUlTs
Broad, specific, and Persistent T cell 
responses after hiVBr18 immunization 
coadministered with P. acnes
To evaluate the adjuvant effect of P. acnes and whether its soluble 
PS fraction mediates bacterium action on the immunogenicity 
of HIVBr18, mice were administered the DNA vaccine alone 
or with the adjuvant in the first or in both doses. After 2 weeks, 
the cellular immune response was assessed, and compared to 
HIVBr18 alone (201 SFU/106 cells) and P. acnes in both doses 
(201.8 SFU/106 cells), addition of P. acnes to only the first dose was 
found to significantly increase the number of IFN-γ producing 
cells (343.1 SFU/106 cells) (Figure 1A). In contrast, 10 weeks after 
the last dose, mice that received HIVBr18 with P. acnes in both 
doses expressed a higher number of IFN-γ-producing cells (202.5 
SFU/106 cells) than the other mice (87.3 SFU/106 cells for mice 
that did not receive adjuvant, and 76.4 SFU/106 cells for mice that 
received P. acnes only in the first dose, Figure 1A). As expected, in 
animals immunized with empty vector pVAX1 in the presence of 
P. acnes, the number of these cells was lower than the cutoff value.
Human immunodeficiency virus-specific T cell proliferation 
analysis (Figure  1B) demonstrated that, 2  weeks postimmuni-
zation with HIVBr18, the presence of P. acnes in the first or in 
both doses enhanced the frequency of CD4+ T  lymphocytes to 
a greater degree than the absence of adjuvant (7.53, 5.16, and 
2.51%, respectively). Although the frequency of CD8+ proliferat-
ing T cells was also higher in the groups that received P. acnes, 
the group that received two doses of this adjuvant showed a 
significantly higher frequency (4.9%) of proliferating cells than 
the group that received P. acnes with the first dose (3.85%) and 
the group that received no adjuvant (1.83%). Even 10  weeks 
after the last immunization, the presence of P. acnes in the first 
or in both doses induced a higher frequency of proliferation of 
HIV-1-specific CD4+ (6.35 and 6.69%, respectively) and CD8+ 
(6.07 and 7.38%, respectively) T cells than the group that received 
no adjuvant (4.10% for CD4+ and 2.37% for CD8+ T cells). As 
expected, immunization with pVAX1 did not generate detectable 
HIV-1-specific T cell proliferation.
The addition of PS to HIVBr18 also increased the magnitude 
of IFN-γ production (Figure 1C) 2 weeks after the last immuni-
zation when administered in the first dose (411 SFU/106 cells) 
and in both doses (495.6 SFU/106 cells). As expected, in pVAX1-
expressing mice that were immunized in the presence of PS, the 
number of IFN-γ-producing cells was below the cutoff value. 
Administration of PS in the first dose also induced higher HIV-
1-specific CD4+ T cell proliferation (4.73%) than the absence of 
adjuvant (2.51%) and administration of PS in both doses (2.56%) 
(Figure  1D). Regarding the CD8+ T  cell component, the PS 
adjuvant effect was more prominent, such that administration of 
PS increased the frequency of these HIV-1-specific cells in both 
groups of animals that received PS (7.76 and 4.6%, Figure 1D). As 
expected, spleen cells from pVAX1-immunized mice presented 
low levels of proliferation. However, different from P. acnes treat-
ment, PS administration in the first or in both doses could not 
maintain the magnitude of the cellular response for 10  weeks, 
neither on IFN-γ producing cells (121.7 and 129.3 SFU/106 cells, 
Figure  1C) nor on the frequency of proliferating (Figure  1D) 
CD4+ (2.63 and 3.63%, respectively) and CD8+ T cells (1.27 and 
1.73%, respectively).
The breadth of the HIV-1-specific cellular response could 
be another factor indicating the effect of P. acnes as an adjuvant 
on the DNA vaccine HIVBr18 and the respective role of PS in 
this evaluation. Spleen cells from immunized mice were then 
FigUre 1 | The magnitude of specific cellular responses to the pool of human immunodeficiency virus (HIV)-1 peptides induced by HIVBr18 was potentiated and 
persisted when mice were immunized in the presence of Propionibacterium acnes. Two or 10 weeks after the last immunization with empty vector pVAX1 or 
HIVBr18, with or without P. acnes (a,B) or polysaccharide (c,D), splenocytes were either cultured for 18 h with pooled HIV-1 peptides and evaluated for IFN-γ 
production by ELISpot assay (a,c) or stained with carboxyfluorescein succinimidyl ester (CFSE) (1.25 µM) before culturing with the pooled peptides for 5 days 
(B,D). Antigen-specific proliferation was defined by CFSE dilution in gated CD3+CD4+ and CD3+CD8+ cells by flow cytometry. SFU, spot-forming units. Cutoff = 15 
SFU/106 cells. Results are presented as values (mean ± SD) for each group from three independent experiments. *p < 0.05; **p < 0.001; ***p < 0.0001.
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separately cultured in the presence of 1 of the 18 peptides encoded 
by HIVBr18. After 2 weeks, we detected that the breadth of the 
cellular response was significantly enhanced when HIVBr18 was 
delivered with P. acnes (Figure 2A) or PS (Figure 2D), which was 
indicated by the average of recognized peptides (Figures 2C,F). 
Splenocytes from mice immunized with P. acnes recognized 15 
peptides, and of these 15, mice immunized with PS recognized 14, 
and mice immunized without adjuvant recognized 6. Moreover, 
the magnitude of the response to most of the recognized pep-
tides, i.e., SFU value, was higher in the groups that received the 
adjuvants (Figures  2A,D). Thus, evaluating the HIV-1-specific 
response via IFN-γ production, coadministration of P. acnes or 
PS was able to enhance not only the magnitude but also the range 
of the response.
Ten weeks after the last dose, only the group that received 
two doses of the DNA vaccine HIVBr18, both coadministered 
with P. acnes, sustained the closest number (14 peptides) of 
recognized peptides (Figure 2C). However, groups that received 
 P. acnes only in the first dose, or received PS in one or both doses, 
responded to fewer peptides (9, 10, and 11 peptides respectively, 
Figures  2C,F). Nevertheless, while the magnitude of positive 
peptide responses also remained high in both P. acnes groups 
(Figure 2B), this effect was not observed with PS (Figure 2E). 
Thus, even for the group that received a single dose of P. acnes 
and had a decrease in the number of peptides recognized over 
time, the magnitude of the positive peptides was still higher 
than that observed for PS.
improvement of the Th1 response and  
the Polyfunctional Profile of the cellular 
immune response after coadministration 
of hiVBr18 with P. acnes or Ps
Results of the ELISpot assay for IFN-γ revealed that the presence 
of P. acnes, or its PS component, in HIVBr18 immunization was 
able to induce a driven Th1 response. Thus, splenocyte culture 
supernatants were evaluated using a cytometric bead array to 
assess the cytokine profile (Figure 3). The presence of P. acnes 
(Figure 3A) in the first or in both doses generated significantly 
higher concentrations of IFN-γ (4,012 and 3,027 pg/mL, respec-
tively), IL-6 (408 and 249  pg/mL, respectively), and TNF-α 
(185 pg/mL, when P. acnes was administered in the first dose), 
FigUre 2 | Immunization with HIVBr18 in the presence of Propionibacterium acnes or its soluble polysaccharide (PS) fraction increased the magnitude and range of 
IFN-γ production against the human immunodeficiency virus (HIV)-1 peptides, in a persistent manner. Two or 10 weeks after the last immunization with HIVBr18, in 
the presence of P. acnes [(a) for 2 weeks and (B) for 10 weeks] or PS [(D), for 2 weeks, and (e), for 10 weeks], spleen cells were separately cultured with each of 
the 18 peptides for 18 h and evaluated for the magnitude and range of IFN-γ production by ELISpot assay. The number of recognized epitopes (c,F) was defined 
when IFN-γ production was above the cutoff value. SFU, spot-forming units. Cutoff = 15 SFU/106 cells (dotted line). Results are presented as values (mean ± SD) 
from three independent experiments.
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than the absence of adjuvant (2,158, 208, and 123 pg/mL, respec-
tively). However, higher concentrations of IL-10 (181 pg/mL) and 
IL-17 (390 pg/mL) were detected with the absence of adjuvants 
(control group) than with the groups that received P. acnes in 
the first or in both doses (130 and 112 pg/mL for IL-10, and 157 
and 215 pg/mL for IL-17). Levels of IL-4 and IL-2 cytokines were 
below the detection limit.
Coadministration of PS (Figure 3B) induced higher levels of 
type I cytokines, such as IFN-γ and TNF-α, than control group. 
However, compared to the level obtained with P. acnes treat-
ment, there was an increase in the levels of IL-10 when PS was 
administered in the first or in both doses (412 and 298 pg/mL, 
respectively) and of IL-17 (436 pg/mL) when PS was adminis-
tered in the first dose.
To evaluate whether the adjuvant would affect the phenotypic 
and functional profile of HIV-1-specific T  cells, we used mul-
tiparametric flow cytometry. As shown in Figure 4A, administra-
tion of P. acnes in the first dose of HIVBr18 induced a higher 
frequency of CD4+ T  lymphocytes that proliferated and produced 
any combination of IFN-γ, IL-2, and TNF-α (3.22%) than that 
induced by administration of HIVBr18 in the absence of adjuvant 
(2.1%). In addition, Boolean combinations revealed that HIV 
immunization with P. acnes in the first dose increased the fre-
quency of HIV-1-specific polyfunctional CD4+ T  lymphocytes, 
FigUre 3 | Immunization with HIVBr18 in the presence of Propionibacterium acnes or polysaccharide (PS) increased the synthesis of Th1 cytokines against the 
pool of 18 peptides. Two weeks after immunization with empty vector pVAX1 or HIVBr18, in the presence or absence of P. acnes (a) or PS (B), splenocytes were 
cultured for five days with pooled human immunodeficiency virus (HIV)-1 peptides encoded by this DNA vaccine. Cytokines in the supernatant were analyzed using 
the mouse Th1/Th2/Th17 cytokine cytometric bead array (CBA, BD). Results are presented as values (mean ± SD) from a representative experiment of three 
independent experiments. *p < 0.05; **p < 0.001; ***p < 0.0001.
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as determined by the frequency of double positive IFN-γ+/
TNF-α+ (1.09%) or triple positive (0.51%) cells compared to that 
in other groups (Figure 4B). In turn, there was no difference in 
the CD8+ T cell population (Figures 4C,D) such that all groups 
exhibited proliferation of predominantly IFN-γ-producing cells. 
Similarly, the increase in polyfunctional CD4+ T  lymphocytes 
was also observed with coadministration of PS, which increased 
the frequency of CD8+ T lymphocytes that proliferated and pro-
duced IFN-γ, IL-2, and TNF-α in any combination (Figure S2 in 
Supplementary Material).
cytotoxic activity of splenocytes induced 
by immunization with hiVBr18 in 
association to P. acnes
As a functional evaluation of immunization with HIVBr18, the 
ability of splenocytes from immunized mice to induce the lysis 
of cells that potentially present HIV-1 peptides encoded by this 
DNA vaccine was investigated. Spleen cells obtained after the 
last immunization were cultured with a macrophage lineage 
(RAW 264.7) previously transfected with the HIVBr18 vaccine 
FigUre 4 | Coadministration of Propionibacterium acnes and HIVBr18 vaccine induced an increase in human immunodeficiency virus (HIV)-1-specific CD4+ 
T lymphocytes with a polyfunctional profile of type I cytokines. Two weeks after immunization with empty vector pVAX1 or HIVBr18, in the presence or absence 
of P. acnes, spleen cells were stained with CFSE (1.25 µM) before culturing with pooled HIV-1 peptides for five days. In the last 12 h of incubation, cells were 
restimulated with Brefeldin A and anti-CD28. After extracellular (CD3, CD4, and CD8) and intracellular staining (IFN-γ, TNF-α, and IL-2), the cells were analyzed 
by flow cytometry. Panels (a,c), respectively, demonstrate the total frequencies of CD4+ and CD8+ T lymphocytes, which proliferated and produced cytokines 
against the stimulus. Panels (B,D) demonstrate the Boolean combinations that, respectively, determine the CD4+ and CD8+ T lymphocytes that proliferated and 
produced one or more cytokines, using the FlowJo software. Results are presented values (mean ± SD) from three independent experiments. *p < 0.05; 
**p < 0.001; ***p < 0.0001.
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or with the empty vector and incubated with [methyl-3H] 
thymidine.
The group that received P. acnes was found to be able to 
induce significant specific lysis (6.37%) when compared to the 
group immunized with the DNA vaccine alone, which presented 
undetectable values of specific lysis (Figure 5).
DiscUssiOn
Herein, we have demonstrated the adjuvant effect of heat-killed 
P. acnes suspension, which is known to induce a typical Th1 
response, in the immunogenicity of HIVBr18. Specifically, 
P. acnes enhanced the magnitude and range of the response, 
FigUre 5 | Coadministration of Propionibacterium acnes and HIVBr18 DNA vaccine promoted cytotoxic activity of splenocytes against transfected cells. Two 
weeks after the last immunization with two doses of HIVBr18 alone, or with P. acnes in the first dose, spleen cells were obtained and cultured with a macrophage 
lineage that was previously transfected with the HIVBr18 vaccine plasmid or with empty vector (pVAX1), and then, samples were incubated with [methyl-3H] 
thymidine. Cells were maintained at the proportion of 1 target to 50 effector cells under an atmosphere of 5% CO2 at 37°C for 3.5 h. Then, cells were collected in a 
cell harvester, and the radioactivity was measured in a β-counter and converted to lysis percentage (a). Specific lysis was evaluated by subtracting the lysis value 
obtained when target cells were transfected with HIVBr18 from the lysis value obtained when target cells were transfected with empty pVAX1 (B). Results are 
presented as values (mean ± SD) from a representative experiment of two independent experiments. *p < 0.05.
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increasing the number of recognized peptides. Moreover, even 
with few immunizations, this adjuvant increased the polyfunc-
tional profile of CD4+ T cells and prolonged the vaccine-induced 
immune response. Furthermore, combining the adjuvant P. acnes 
with HIVBr18 immunization induced lymphocyte cytotoxicity to 
vaccine plasmid-transfected targets.
In this study, reduction in the number of doses used [com-
parable to the three-dose schedule demonstrated in previous 
studies (23, 24); Figure S3 in Supplementary Material], and the 
greater breadth of the response obtained by the coadministra-
tion the DNA vaccine and P. acnes could be explained by the 
direct action of this adjuvant on DCs, macrophages and B-2 
lymphocytes, i.e., APCs, which has been previously described by 
us and others (41, 52, 53, 56). A DNA vaccine primes immune 
responses after intramuscular injection, transfecting mainly 
myocytes, as well as other immune cells found within the muscle, 
such as DCs and monocytes (64, 65). Transfection of these cells, 
or phagocytosis of transfected dead or dying cells by these cells, 
enables the generation of the immune response through MHC 
I and/or MHC II pathways, thus priming CTLs and activating 
CD4+ T helper lymphocytes (66–69). Therefore, we believe that 
the most appropriate adjuvant for DNA vaccine should be the one 
that potentiates APCs.
Direct effects of P. acnes on DC maturation have been 
described in vitro (52–54) and in vivo, such that previous studies 
observed an increase in DC precursors in the liver and blood 
of mice after treatment with P. acnes (70, 71) and an increase 
in the number and activation status of bone marrow-derived 
DCs (56). The function of P. acnes and the role of its soluble PS 
component in the activation status of these cells and other APCs 
have been well investigated. In a murine model of hypersensi-
tivity to ovalbumin (OVA), potentiation of the Th2 response 
occurred when P. acnes or PS treatment coincided with OVA 
administration, but a typical Th1 response occurred when mice 
were treated with the adjuvant before OVA sensitization (55, 57). 
The potentiated OVA-Th2 responses induced by P. acnes and PS 
rely on directed cytokine production, a significant increase in the 
number of APCs expressing costimulatory molecules, such as 
CD40 (except PS), CD80, and CD86, and upregulation of these 
three molecules by mainly macrophages and DCs. However, 
when Th2 was suppressed, increased expression levels of TLR2, 
TLR4 and intracellular TLR9 in B cells and DCs and extracellular 
TLR9 in B  cells and macrophages, with increasing numbers of 
IL-12+ cells, were observed. Several studies demonstrated the 
relationship between TLR2 and TLR4 signaling and the induc-
tion of Th1 or suppression of Th2 responses in allergic diseases 
(72–75). It was also shown that innate immune cells could be 
directly activated by P. acnes via TLR2 and TLR9 (48, 49), thus 
inducing proinflammatory cytokine synthesis (76). Moreover, 
P. acnes is known to induce production of proinflammatory 
cytokines, such as IL-18 (77–80), and in combination with IL-12, 
IL-18 may be responsible for directing the T helper response, 
resulting in IFN-γ secretion. Therefore, we can speculate that 
the influence of this adjuvant on APCs—such as improving the 
cell-mediated immune response (evaluated by IFN-γ production 
and T cell proliferation), increasing the response magnitude and 
significantly improving the response range (by increasing the 
number of recognized peptides)—can explain its impact on the 
immunogenicity of the HIVBr18 vaccine.
A broad T cell response against conserved epitopes is an essen-
tial condition for protection, as demonstrated by T  cell-based 
HIV vaccine trials (20, 81, 82). For example, in the STEP trial, an 
adenovirus 5-based HIV vaccine encoding three HIV proteins 
(Gag, Pol, and Nef) induced an average recognition of only three 
epitopes per participant but in conserved and variable regions 
of the sequence. This vaccine failed to reduce the viral load in 
infected individuals and to prevent HIV-1 infection (20, 82, 83). 
In addition, the induction of simultaneous, vaccine-specific CD4+ 
10
Teixeira et al. HIV-1 Vaccine Improvement by P. acnes
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 177
and CD8+ T cell responses was limited to 25% of the patients. 
However, an adenovirus 5-based SIV vaccine encoding eight 
SIV proteins promoted a broad CD4+ and CD8+ T lymphocyte 
response in vaccinated non-human primates, allowing viremia 
control after challenge (84).
Unmethylated regions of DNA—such as cytosine-phosphate-
guanine oligonucleotide sequences (CpG), which are also com-
mon in bacterial genomes—incorporated into DNA vaccines 
are recognized by TLR9 and induce APC-dependent production 
of proinflammatory cytokines, i.e., IL-12 and IFN type I, and 
thus, these regions act as an immune response adjuvant (85, 86). 
Similarly, P. acnes effects are associated with the induction and 
activation of intracellular and extracellular TLR9 in APCs (49, 58) 
by inducing the release of Th1 cytokines (87) and IgG2a switch, 
which is also related to the Th1 pattern (88). This direction to 
the Th1 pattern was observed both in the Th2 suppression in the 
type I hypersensitivity murine model described above and using 
a DNA vaccine containing T. cruzi trans-sialidase gene when a 
higher synthesis of IFN-γ and reduction of IgG1/IgG2a ratio (41) 
were demonstrated. Indeed, coadministration of HIVBr18 and 
P. acnes increased IFN-γ and TNF-α production but decreased 
IL-10 production, confirming the Th1 pattern generated by this 
vaccine (24) and suggesting a greater Th1 polarization upon 
coadministration of P. acnes. Interestingly, immunization with 
a DNA vaccine in the presence of P. acnes led to a decrease in 
vaccine-specific IL-17 cytokine levels. Moreover, the Th17 
response during HIV infection is controversial (89). IL-17A is 
involved in maintaining the integrity of the epithelial barrier 
(90, 91), and depletion of gut-associated lymphoid tissue Th17 
and Th1/Th17 lymphocytes was shown to be the main cause of 
chronic immune activation and non-AIDS-related comorbidities 
in infected individuals (92). However, Th17 cells have been shown 
to be pathogenic due to their permissiveness to viral infection 
because they carry integrated HIV-DNA and contribute to per-
sistent reservoirs of HIV under antiretroviral treatment (89, 93).
Intensive investigations of adjuvants that increase the immuno-
genicity of DNA vaccination have previously demonstrated that 
coadministration of cytokine genes significantly enhances the 
immune response (60, 94–97). In a recent work, coadministra-
tion of the HIVBr18 DNA vaccine and a plasmid encoding 
granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(60) increased the frequency of polyfunctional HIV-specific 
T lymphocytes (IFN-γ+ TNF-α+ IL-2+). As such, these findings 
may be related to the increase in these polyfunctional cells 
observed following coadministration of HIVBr18 and P. acnes. 
A previous study reported an increase in the synthesis of hemat-
opoietic cytokines, such as GM-CSF, in animals treated with 
P. acnes (98), when then induced an increase in the number of 
bone marrow stem cells and the maturation of DCs (56). HIV-
specific and polyfunctional CD4+ T lymphocytes were shown to 
be more frequent in long-term non-progressor patients than in 
patients who rapidly progressed to AIDS (99, 100). Therefore, the 
polyfunctional responses of HIV-specific CD4+ T cells might be 
potentiated by the presence of P. acnes and might contribute to 
the control of disease progression (101–106). We also observed 
higher levels of Th1 cytokines when P. acnes was administered in 
the first dose than when it was administered in both doses. This 
result could be explained due to cytokine receptor exhaustion or 
even their delayed turnover.
The levels of IFN-γ-producing cells and proliferating HIV-
specific CD4+ and CD8+ T  lymphocytes 10 weeks after the last 
dose demonstrated that the coadministration of P. acnes with 
both HIV-1 vaccinations is important for longevity of the cel-
lular response. The CD4+ T lymphocyte response was previously 
reported to persist for up to 24 weeks when the DNA vaccine was 
administered in three doses with a central memory element (24). 
A vaccine capable of inducing CD4+ and CD8+ effector memory 
responses was previously shown to also prevent progressive sys-
temic infection in animals challenged with highly pathogenic SIV, 
even in the absence of neutralizing antibodies (107). Therapeutic 
vaccination of monkeys with SIV-specific DNA vaccine with 
coadministration of IL-12 and IL-15 plasmids enhanced the 
specific population of CD8+ memory cells and their production 
of cytokines (97). Modulation of both innate and acquired immu-
nity by inducing proinflammatory cytokines, including IL-12, 
may be one of the mechanisms by which P. acnes could modulate 
the population of memory cells (108), and this mechanism may 
be associated with the higher frequency of IFN-γ-producing cells 
and the increased number of recognized peptides.
As expected and as demonstrated in our previous studies, 
herein, PS is one of the main components of P. acnes responsible 
for the outcomes observed when using the whole bacterium. PS 
substantially increased the number of cells that specifically pro-
duced IFN-γ and increased the amplitude of recognized peptides, 
the frequency of HIV-specific T lymphocytes (especially the CD8+ 
population), the cytokine pattern (regarding the production of 
type I cytokines), and the number of CD4+ polyfunctional T cells. 
The presence of other compounds in the whole bacterium (pro-
teins and lipids) could explain the differences observed between 
P. acnes and PS treatments, notably the absence of a significant 
cognate memory T  cell population and a persistent cellular 
response. However, as demonstrated in previous studies, PS had 
an undeniable effect in inducing TLR2, TLR4, extracellular and 
intracellular TLR9 in APCs and B-1 cells (58, 109).
We also found that immunization with the HIVBr18 vaccine, 
in the presence of P. acnes, induced an increased HIV-1-specific 
cytotoxic activity against target cells transfected with the same 
plasmid. These target cells could express the majority of epitopes 
encoded by the DNA vaccine, and herein, the effector cells were 
found to be able to respond to a large spectrum of epitopes when 
the adjuvant was coadministered with the vaccine. This activity 
could be explained by the induction of the Th1 response pattern 
by the effector pool when P. acnes was administered. In addition 
to these mediators of the adaptive immune response, the adjuvant-
potentiated increase in IFN-γ levels could also affect cells with 
cytotoxic activities, such as macrophages, NK and NKT  cells. 
Published data from our laboratory and others have shown an 
increased cytotoxic activity of macrophages and NKT cells with 
high levels of TNF-α and NO release induced by P. acnes and its 
PS fraction (36–38, 110).
A DNA vaccine, such as HIVBr18 vaccine, can induce a potent 
and persistent response of CD4+ T  cells with a polyfunctional 
phenotype and thus can facilitate the cytotoxic activity of these 
cells. As previously shown in the literature, this type of DNA 
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vaccine may have a protective effect against SIV/HIV infection 
(15, 18, 19, 22, 84, 99–106). In summary, the adjuvant effect of 
coadministration of P. acnes with HIVBr18 was evidenced by the 
potentiation of these responses and the increase in the number of 
recognized peptides, which generated a broader and more per-
sistent response and reduced the number of administered doses. 
Given the promising use of P. acnes in humans, the enhanced 
responses against conserved HIV-1 regions, such as those 
observed by coadministering HIVBr18 and P. acnes, might 
control viral replication in individuals who became infected after 
immunization not only by limiting viral transmission but also by 
preventing progression to HIV-associated disease.
eThics sTaTeMenT
This study was carried out in strict accordance with the recom-
mendations of the National Institutes of Health Guide for the 
Care Use of Laboratory Animals and the Brazilian National Law 
(11.794/2008). The protocol was approved by the Institutional 
Animal Care and Use Committee (IACUC) of the Federal 
University of São Paulo and by the Ethics Committee of University 
of São Paulo School of Medicine (permit number 4836281114).
aUThOr cOnTriBUTiOns
DT and IM conceived and designed the experiments. DT, MI, 
JA, JV, and VP performed the experiments. DT, MI, JV, and 
VP analyzed the data and prepared the figures. DT, MI, and 
IM wrote the manuscript. IM, DR, and EC-N performed the 
final review of the article. All authors read and approved the 
final article.
acKnOWleDgMenTs
The authors would like to thank Mr. Geová Santos for animal 
care at UNIFESP/EPM. The authors also thank Renato Arruda 
Mortara and Carina Carrara for providing the RAW 264.7 cell 
line and FuGENE® HD Transfection Reagent for cytotoxicity 
assays.
FUnDing
This research was supported by the Fundação de Amparo à 
Pesquisa do Estado de São Paulo (FAPESP, 2014/25307-4), 
Conselho Nacional de Desenvolvimento Científico e Tecnológico 
(CNPq) and Coordenação de Aperfeiçoamento de Pessoal de 
Nível Superior (CAPES).
sUPPleMenTarY MaTerial




1. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, 
et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) 
from patients with AIDS and at risk for AIDS. Science (1984) 224:500–3. 
doi:10.1126/science.6200936 
2. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, 
Gruest J, et  al. Isolation of a T-lymphotropic retrovirus from a patient at 
risk for acquired immune deficiency syndrome (AIDS). Science (1983) 
220:868–71. doi:10.1126/science.6189183 
3. UNAIDS/WHO 2016. AIDS by the Numbers. AIDS Is not Over, But It 
Can Be. (2016) Available from: http://www.unaids.org/sites/default/files/
media_asset/AIDS-by-the-numbers-2016_en.pdf
4. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogene-
sis, prevention, and treatment. Lancet (2006) 368:489–504. doi:10.1016/
S0140-6736(06)69157-5 
5. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The 
immune response during acute HIV-1 infection: clues for vaccine develop-
ment. Nat Rev Immunol (2010) 10:11–23. doi:10.1038/nri2674 
6. Gandhi RT, Walker BD. Immunologic control of HIV-1. Annu Rev Med 
(2002) 53:149–72. doi:10.1146/annurev.med.53.082901.104011 
7. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the 
human immunodeficiency virus type I (HIV-1)-specific cytotoxic T lympho-
cyte (CTL) response at different stages of HIV-1 infection: differential CTL 
responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med (1993) 
177:249–56. doi:10.1084/jem.177.2.249 
8. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cyto-
pathocity correlate temporally with CD4+ T-lymphocyte decline and clinical 
progression in human immunodeficiency virus type 1-infected individuals. 
J Virol (1993) 67:1772–7. 
9. McElrath MJ, Haynes BF. Induction of immunity to human immunodefi-
ciency virus type-1 by vaccination. Immunity (2010) 33:542–54. doi:10.1016/j.
immuni.2010.09.011 
10. Klatt NR, Silvestri G. CD4+ T cells and HIV: a paradoxical pas de deux. Sci 
Transl Med (2012) 4:123s4. doi:10.1126/scitranslmed.3003862 
11. Shedlock DJ, Shen H. Requirement for CD4 T  cell help in generating 
functional CD8 T  cell memory. Science (2003) 300:337–9. doi:10.1126/
science.1082305 
12. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, 
et  al. Loss of HIV-1-specific CD8+ T  cell proliferation after acute HIV-1 
infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. 
J Exp Med (2006) 200:701–12. doi:10.1084/jem.20041270 
13. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, 
Kalams SA, et al. Vigorous HIV-1-specific CD4(+) T cell responses associated 
with control of viremia. Science (1997) 278:1447–50. doi:10.1126/science.278. 
5342.1447 
14. Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, 
et  al. Beyond help: direct effector functions of human immunodeficiency 
virus type 1-specific CD4(+) T cells. J Virol (2004) 78:8844–51. doi:10.1128/
JVI.78.16.8844-8851.2004 
15. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, 
Chung C, et al. Gag- and Nef-specific CD4(+) T cells recognize and inhibit 
SIV replication in infected macrophages early after infection. Proc Natl Acad 
Sci U S A (2009) 106:9791–6. doi:10.1073/pnas.0813106106 
16. Von Gegerfelt A, Valentin A, Alicea C, Van Rompay KK, Marthas ML, 
Montefiori DC, et al. Emergence of simian immunodeficiency virus-specific 
cytotoxic CD4+ T  cells and increased humoral responses correlate with 
control of rebounding viremia in CD8-depleted macaques infected with Rev-
independent live-attenuated simian immunodeficiency virus. J Immunol 
(2010) 185:3348–58. doi:10.4049/jimmunol.1000572 
17. Pancre V, Delhem N, Yazdanpanah Y, Delanoye A, Delacre M, Depil S, 
et  al. Presence of HIV-1 Nef specific CD4 T  cell response is associated 
with non-progression in HIV-1 infection. Vaccine (2007) 25:5927–37. 
doi:10.1016/j.vaccine.2007.05.038 
18. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, 
Pertel T, et  al. HIV-specific cytolytic CD4 T  cell responses during acute 
12
Teixeira et al. HIV-1 Vaccine Improvement by P. acnes
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 177
HIV infection predict disease outcome. Sci Transl Med (2012) 4:123–5. 
doi:10.1126/scitranslmed.3003165 
19. Vaccari M, Mattapallil J, Song K, Tsai WP, Hryniewicz A, Venzon D, et al. 
Reduced protection from simian immunodeficiency virus SIVmac251 infec-
tion afforded by memory CD8+ T cells induced by vaccination during CD4+ 
T-cell deficiency. J Virol (2008) 82(19):9629–38. doi:10.1128/JVI.00893-08 
20. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launch-
ing point for future vaccine development? J Exp Med (2008) 205:7–12. 
doi:10.1084/jem.20072681 
21. Watkins DI. The hope for an HIV vaccine based on induction of CD8(+) 
T  lymphocytes—a review. Mem Inst Oswaldo Cruz (2008) 103:119–29. 
doi:10.1590/S0074-02762008000200001 
22. Fonseca SG, Coutinho-Silva A, Fonseca LA, Segurado AC, Moraes SL, 
Rodrigues H, et al. Identification of novel consensus CD4 T-cell epitopes from 
clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected 
patients. AIDS (2006) 20:2263–73. doi:10.1097/01.aids.0000253353.48331.5f 
23. Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postól E, Oliveira SC, et al. 
A vaccine encoding conserved promiscuous HIV CD4 epitopes induces 
broad T cell responses in mice transgenic to multiple common HLA class II 
molecules. PLoS One (2010) 5:6. doi:10.1371/journal.pone.0011072 
24. Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Postól E, Kalil J, et  al.  
A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous poly-
functional, long-lived CD4(+) and CD8(+) T cell responses. PLoS One (2011) 
6:2. doi:10.1371/journal.pone.0016921 
25. Apostolopoulos V, Weiner DB. Development of more efficient and effective 
DNA vaccines. Expert Rev Vaccines (2009) 8(9):1133–4. doi:10.1586/erv.09.94 
26. Hokey DA, Weiner DB. DNA vaccines for HIV: challenges and opportu-
nities. Springer Semin Immunopathol (2006) 28(3):267–79. doi:10.1007/
s00281-006-0046-z 
27. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB, et  al. 
Immunogenicity of novel consensus-based DNA vaccines against avian 
influenza. Vaccine (2007) 25(16):2984–9. doi:10.1016/j.vaccine.2007.01.063 
28. Schoenly KA, Weiner DB. Human immunodeficiency virus type 1 vaccine 
development: recent advances in the cytotoxic T-lymphocyte platform 
“spotty business”. J Virol (2008) 82(7):3166–80. doi:10.1128/JVI.01634-07 
29. Joseph S, Quinn K, Greenwood A, Cope AV, McKay PF, Hayes PJ, et  al.  
A comparative phase I study of combination, homologous subtype-C DNA, 
MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization 
regimes. Front Immunol (2017) 8:149. doi:10.3389/fimmu.2017.00149 
30. Leyden JJ, McGinley KJ, Mills O, Kligman AM. Age-related changes in the 
resident bacterial flora of the human face. J Invest Dermatol (1974) 65:379–81. 
doi:10.1111/1523-1747.ep12607630 
31. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev 
Oncol Hematol (2002) 44:81. doi:10.1016/S1040-8428(02)00014-8 
32. Shepherd FA. Alternatives to chemotherapy and radiotherapy as adjuvant 
treatment for lung cancer. Lung Cancer (1997) 17(Suppl 1):S121. doi:10.1016/
S0169-5002(97)00646-6 
33. Halpern BN, Pr’Evot AR, Biozzi G, Stiffel C, Mouton D, Morard JC, et al. 
[Stimulation of the phagocytic activity of the reticuloendothelial system by 
Corynebacterium parvum]. J Reticuloendothel Soc (1964) 83:77–96. 
34. Woodruff MF, McBride WH, Dunbar N. Tumour growth, phagocytic activity 
and antibody response in Corynebacterium parvum-treated mice. Clin Exp 
Immunol (1974) 17:509–18. 
35. Halpern BN, Biozzi G, Stiffel C, Mouton D. Inhibition of tumour growth by 
administration of killed Corynebacterium parvum. Nature (1966) 212:853–4. 
doi:10.1038/212853a0 
36. Ghaffar A, Cullen RT, Woodruff MA. Further analysis of the anti-tumour 
effect in  vitro of peritoneal exudate cells from mice treated with Coryneb­
acterium parvum. Br J Cancer (1975) 31:15–24. doi:10.1038/bjc.1975.3 
37. Keller R, Keist R, van der Meide PH. Modulation of tumoricidal activity, 
induced in bone-marrow-derived mononuclear phagocytes by interferon 
gamma or Corynebacterium parvum, by interferon beta, tumor necrosis 
factor, prostaglandin E2, and transforming growth factor beta. Int J Cancer 
(1991) 49:796–800. doi:10.1002/ijc.2910490526 
38. Ananias RZ, Rodrigues EG, Braga EG, Squaiella CC, Mussalem JS, 
Longhini ALF, et  al. Modulatory effect of killed-Propionibacterium acnes 
and its purified soluble polysaccharide on peritonial exudate cells from 
C57Bl/6 mice: major NKT cell recruitment and increased cytotoxicity. Scand 
J Immunol (2007) 65:538–48. doi:10.1111/j.1365-3083.2007.01939.x 
39. Kennedy JD, Sutton RC, Conley FK. Effect of intracerebrally injected 
Corynebacterium parvum on the development and growth of metastatic 
brain tumor in mice. Neurosurgery (1989) 25:709–14. doi:10.1227/00006123- 
198911000-00004 
40. Warr GW, James K. Effect of Corynebacterium parvum on the class and 
subclass of antibody produced in the response of different strains of mice to 
sheep erythrocytes. Immunology (1975) 28:431–42. 
41. Mussalem JS, Vasconcelos JR, Squaiella CC, Ananias RZ, Braga EG, 
Rodrigues MM, et al. Adjuvant effect of the Propionibacterium acnes and its 
purified soluble polysaccharide on the immunization with plasmidial DNA 
containing a Trypanosoma cruzi gene. Microbiol Immunol (2006) 50:253–63. 
doi:10.1111/j.1348-0421.2006.tb03791.x 
42. Nussenzweig R. Increased nonspecific resistance to malaria produced by 
administration of killed Corynebacterium parvum. Exp Parasitol (1967) 
21:224. doi:10.1016/0014-4894(67)90084-7 
43. Brener Z, Cardoso JE. Nonspecific resistance against Trypanosoma cruzi 
enhanced by Corynebacterium parvum. J Parasitol (1967) 62:645–6. 
doi:10.2307/3279437 
44. Ha DK, Lawton JW, Gardner ID. The effect of in vivo modulation of macro-
phage activities on Mycobacterium lepraemurium infection. J Comp Pathol 
(1986) 96:565–73. doi:10.1016/0021-9975(86)90077-0 
45. Hill JO. Modulation of the pattern of development of experimental dis-
seminated leishmaniasis by Corynebacterium parvum. J Leukoc Biol (1986) 
41:165–9. doi:10.1002/jlb.41.2.165 
46. Abath FG, Coutinho EM, Montenegro SM, Gomes YM, Carvalho AB. The 
use of non-specific immunopotentiators in experimental Trypanosoma 
cruzi infection. Trans R Soc Trop Med Hyg (1988) 82:73–6. doi:10.1016/ 
0035-9203(88)90268-4 
47. Squaiella CC, Braga EG, Ananias RZ, Longhini ALF, Mussalem JS, 
Silva RM, et al. Longo-Maugéri, I. M. Efeito do tratamento de camundongos 
com Propionibacterium acnes sobre a resposta específica e atividade de 
células do sistema imune na infecção por Klebsiella pneumoniae. Anais do IX 
Congresso de Iniciação Científica – PIBIC. (Vol. 1), São Paulo, Brazil (2001). 7 p.
48. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, et  al. 
Activation of toll-like receptor 2 in acne triggers inflammatory cytokine 
responses. J Immunol (2002) 169:1535–41. doi:10.4049/jimmunol.169.3.1535 
49. Kalis C, Gumenscheimer M, Freudenberg N, Tchaptchet S, Fejer G, 
Heit A, et  al. Requirement for TLR9 in the immunomodulatory activity 
of Propionibacterium acnes. J Immunol (2005) 174:4295–300. doi:10.4049/
jimmunol.174.7.4295 
50. Velayudham A, Hritz I, Dolganiuc A, Mondrekar P, Kurt-Jones E, Szabo G. 
Critical role of Toll-like receptors and the common TLR adaptor, MyD88, 
in induction of granulomas and liver injury. J Hepatol (2006) 45:813–24. 
doi:10.1016/j.jhep.2006.06.017 
51. Gambero M, Teixeira D, Butin L, Ishimura ME, Mariano M, Popi AF, 
et  al. Propionibacterium acnes induces an adjuvant effect in B-1 cells and 
affects their phagocyte differentiation via a TLR2-mediated mechanism. 
Immunobiology (2006) 221(9):1001–11. doi:10.1016/j.imbio.2016.03.003 
52. MacDonald AS, Straw AD, Bauman B, Pearce EJ. CD8-dendritic cell activa-
tion status plays an integral role in influencing Th2 response development. 
J Immunol (2001) 167:1982–8. doi:10.4049/jimmunol.167.4.1982 
53. MacDonald AS, Straw AD, Dalton NM, Pearce EJ. Cutting edge: Th2 response 
induction by dendritic cells: a role for CD40. J Immunol (2002) 168:537–40. 
doi:10.4049/jimmunol.168.2.537 
54. Cervi L, MacDonald AS, Kane C, Dzierszinski F, Pearce EJ. Cutting edge: 
dendritic cells copulsed with microbial and helminth antigens undergo 
modified maturation, segregate the antigens to distinct intracellular com-
partments, and concurrently induce microbe-specific Th1 and helminth- 
specific Th2 responses. J Immunol (2004) 172:2016–20. doi:10.4049/jimmunol. 
172.4.2016 
55. Squaiella CC, Longhini ALF, Braga EG, Mussalem JS, Ananias RZ, 
Yendo TM, et al. Modulation of the type I hypersensitivity late phase reaction 
to OVA by Propionibacterium acnes-soluble polysaccharide. Immunol Lett 
(2008) 121:157–66. doi:10.1016/j.imlet.2008.10.005 
56. Squaiella CC, Ananias RZ, Mussalem JS, Braga EG, Rodrigues EG, 
Travassos LR, et  al. In vivo and in  vitro effect of killed Propionibacterium 
acnes and its purified soluble polysaccharide on mouse bone marrow stem 
cells and dendritic cell differentiation. Immunobiology (2006) 211:105–16. 
doi:10.1016/j.imbio.2005.10.013 
13
Teixeira et al. HIV-1 Vaccine Improvement by P. acnes
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 177
57. Braga EG, Ananias RZ, Mussalem JS, Squaiella CC, Longhini AL, Mariano M, 
et al. Treatment with Propionibacterium acnes modulates the late phase reac-
tion of immediate hypersensitivity in mice. Immunol Lett (2003) 88:163–9. 
doi:10.1016/S0165-2478(03)00079-8 
58. Squaiella-Baptistão CC, Teixeira D, Mussalem JS, Ishimura ME, Longo-
Maugéri IM. Modulation of Th1/Th2 immune responses by killed- 
Propionibacterium acnes and its soluble polysaccharide fraction: induction of 
different activation status of antigen-presenting cells. J Immunol Res (2015) 
132083:14. doi:10.1155/2015/132083 
59. Ribeiro SP, Apostolico JS, Almeida RR, Kalil J, Cunha-Neto E, Rosa DS. 
Bupivacaine enhances the magnitude and longevity of HIV-specific immune 
response after immunization with a CD4 epitope-based DNA vaccine. Trials 
Vaccinol (2014) 3:95–101. doi:10.1016/j.trivac.2014.05.001 
60. Santana VC, Almeida RR, Ribeiro SP, Ferreira LC, Kalil J, Rosa DS, et  al. 
Co-administration of plasmid-encoded granulocyte-macrophage colony- 
stimulating factor increases human immunodeficiency virus-1 DNA vac-
cine-induced polyfunctional CD4+ T-cell responses. Mem Inst Oswaldo Cruz 
(2015) 110(8):1010–6. doi:10.1590/0074-02760150283 
61. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. Anal 
Biochem (1976) 72:248. doi:10.1016/0003-2697(76)90527-3 
62. Palmer JW, Gerlough TD. Scientific apparatus and laboratory methods. 
Science (1940) 92:155–6. doi:10.1126/science.92.2381.155 
63. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith FA. Colorimetric method 
for the determination of sugars. Nature (1951) 28:167. doi:10.1038/168167a0 
64. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et  al. 
Distribution of DNA vaccines determines their immunogenicity after intra-
muscular injection in mice. J Immunol (2000) 165(5):2850–8. doi:10.4049/
jimmunol.165.5.2850 
65. Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T, et al. 
Targeted antigen delivery to antigen-presenting cells including dendritic cells 
by engineered Fas-mediated apoptosis. Nat Biotechnol (2000) 18(9):974–9. 
doi:10.1038/79470 
66. Rubartelli A, Poggi A, Zocchi MR. The selective engulfment of apoptotic 
bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and 
requires intracellular and extracellular calcium. Eur J Immunol (1997) 
27(8):1893–900. doi:10.1002/eji.1830270812 
67. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. 
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and 
CD36, and cross-present antigens to cytotoxic T  lymphocytes. J Exp Med 
(1998) 188(7):1359–68. doi:10.1084/jem.188.7.1359 
68. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A 
scavenger receptor in dendritic cell nibbling from live cells. J Immunol (2003) 
170(5):2302–9. doi:10.4049/jimmunol.170.5.2302 
69. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. 
J Clin Invest (2002) 109(12):1519–26. doi:10.1172/JCI15962 
70. Yoneyama H, Matsuno K, Zhang Y, Murai M, Itakura M, Ishikawa S, et al. 
Regulation by chemokines of circulating dendritic cell precursors, and the 
formation of portal tract-associated lymphoid tissue, in a granulomatous 
liver disease. J Exp Med (2001) 193:35–49. doi:10.1084/jem.193.1.35 
71. Zhang Y, Yoneyama H, Wang Y, Yshikawa S, Hashimoto S, Gao JL, et  al. 
Mobilization of dendritic cell precursors into the circulation by administra-
tion of MIP-1alpha in mice. J Natl Cancer Inst (2004) 96:201–9. doi:10.1093/
jnci/djh024 
72. Braun-Fahrländer C, Riedler J, Herz U, Eder W, Waser M, Grize L, et  al. 
Environmental exposure to endotoxin and its relation to asthma in school-age 
children. N Engl J Med (2002) 347(12):869–77. doi:10.1056/NEJMoa020057 
73. Lauener RP, Birchler T, Adamski J, Braun-Fahrländer C, Bufe A, Herz U, et al. 
Expression of CD14 and toll-like receptor 2 in farmers’ and non-farmers’ chil-
dren. Lancet (2002) 360(9331):465–6. doi:10.1016/S0140-6736(02)09641-1 
74. Taylor RC, Richmond P, Upham JW. Toll-like receptor 2 ligands inhibit TH2 
responses to mite allergen. J Allergy Clin Immunol (2006) 117(5):1148–54. 
doi:10.1016/j.jaci.2006.02.014 
75. Rodríguez D, Keller AC, Faquim-Mauro EL, de Macedo MS, Cunha FQ, 
Lefort J, et al. Bacterial lipopolysaccharide signaling through toll-like recep-
tor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. 
J Immunol (2003) 171(2):1001–8. doi:10.4049/jimmunol.171.2.1001 
76. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 
21:335–76. doi:10.1146/annurev.immunol.21.120601.141126 
77. Smith SR, Calzetta A, Bankowski J, Kenworthy BL, Terminelli C. 
Lipopolysaccharide-induced cytokine production and mortality in mice 
treated with Corynebacterium parvum. J Leukoc Biol (1993) 54:23–9. 
doi:10.1002/jlb.54.1.23 
78. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. 
Cloning of a new cytokine that induces IFN-gamma production by T cells. 
Nature (1995) 378:88–91. doi:10.1038/378088a0 
79. Matsui K, Yoshimoto T, Tsutsui H, Hyodo Y, Hayashi N, Hiroishi K, et al. 
Propionibacterium acnes treatment diminishes CD4+NK1.1+ T  cells in 
the liver by induction of IL-12 and IL-18 production from Kupffer cells. 
J Immunol (1997) 159:97–106. 
80. Tsuji H, Mukaida N, Harada A, Kaneko S, Matsushita E, Nakanuma Y, 
et  al. Alleviation of lipopolysaccharide-induced acute liver injury in 
Propionibacterium acnes-primed INF-gamma-deficient mice by a concomi-
tant reduction of TNF-alpha, IL-12 and IL-18 production. J Immunol (1999) 
162:1049–55. 
81. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate 
models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 
(2008) 14:617–21. doi:10.1038/nm.f.1759 
82. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 
vaccine-induced immunity in the test-of-concept step study: a case-cohort 
analysis. Lancet (2008) 372:1894–905. doi:10.1016/S0140-6736(08)61592-5 
83. Corey L, McElrath MJ, Kublin JG. Post-step modifications for research on 
HIV vaccines. AIDS (2009) 23:3–8. doi:10.1097/QAD.0b013e32830e6d6d 
84. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, et al. 
Vaccine-induced cellular responses control simian immunodeficiency 
virus replication after heterologous challenge. J Virol (2009) 83:6508–21. 
doi:10.1128/JVI.00272-09 
85. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et  al. A toll-
like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740–5. 
doi:10.1038/35047123 
86. Tudor D, Dubuquoy C, Gaboriau V, Lefevre F, Charley B, Riffault S. TLR9 
pathway is involved in adjuvant effects of plasmid DNA-based vaccines. 
Vaccine (2005) 23(10):1258–64. doi:10.1016/j.vaccine.2004.09.001 
87. Bauer S, Hangel D, Yu P. Immunobiology of toll-like receptors in allergic dis-
ease. Immunobiology (2007) 212(6):521–33. doi:10.1016/j.imbio.2007.03.011 
88. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. 
TLR9 signaling in B cells determines class switch recombination to IgG2a. 
J Immunol (2007) 178(4):2415–20. doi:10.4049/jimmunol.178.4.2415 
89. Wacleche VS, Goulet JP, Gosselin A, Monteiro P, Soudeyns H, 
Fromentin R, et al. New insights into the heterogeneity of Th17 subsets con-
tributing to HIV-1 persistence during antiretroviral therapy. Retrovirology 
(2016) 13(1):59. doi:10.1186/s12977-016-0293-6 
90. Lee JS, Tato CM, Joyce-Shaikh B, Gulan F, Cayatte C, Chen Y, et al. Interleukin-
23-Independent IL-17 production regulates intestinal epithelial permeability. 
Immunity (2015) 43(4):727–38. doi:10.1016/j.immuni.2015.09.003 
91. Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et  al. 
Differential roles for interleukin-23 and interleukin-17 in intestinal immuno-
regulation. Immunity (2015) 43(4):739–50. doi:10.1016/j.immuni.2015.08.019 
92. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, 
consequences and treatment opportunities. Nat Rev Microbiol (2012) 
10:655–66. doi:10.1038/nrmicro2848 
93. Sun H, Kim D, Li X, Kiselinova M, Ouyang Z, Vandekerckhove L, et al. Th1/17 
Polarization of CD4 T cells supports HIV-1 persistence during antiretroviral 
therapy. J Virol (2015) 89:11284–93. doi:10.1128/JVI.01595-15 
94. Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, et al. Feline 
leukemia virus DNA vaccine efficacy is enhanced by coadministration 
with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol (2001) 
75(18):8424–33. doi:10.1128/JVI.75.18.8424-8433.2001 
95. Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY. Protective immune 
responses induced by vaccination with an expression genomic library of 
Leishmania major. J Immunol (1999) 163(3):1467–72. 
96. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, 
et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and 
CD40 ligand trimer induces T  cell-mediated protective immunity against 
colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 
(2001) 167(8):4560–5. doi:10.4049/jimmunol.167.8.4560 
97. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, 
et  al. Therapeutic vaccination with simian immunodeficiency virus 
14
Teixeira et al. HIV-1 Vaccine Improvement by P. acnes
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 177
(SIV)-DNA+ IL-12 or IL-15 induces distinct CD8 memory subsets in 
SIV-infected macaques. J Immunol (2008) 180(12):7969–79. doi:10.4049/
jimmunol.180.12.7969 
98. Foster RS, MacPherson BR, Browdie DA. Effect of Corynebacterium parvum 
on colony-stimulating factor and granulocyte-macrophage colony forma-
tion. Cancer Res (1997) 37:1349–55. 
99. Okoye A, Park H, Rohankhedkar M, Coyne-Johnson L, Lum R, 
Walker JM, et  al. Profound CD4+/CCR5+ T  cell expansion is induced 
by CD8+ lymphocyte depletion but does not account for accelerated SIV 
pathogenesis. J Exp Med (2009) 206:1575–88. doi:10.1084/jem.20090356 
100. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 
(2010) 464:224–31. doi:10.1038/nature08898 
101. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, 
Robinson HL, et al. Human immunodeficiency virus type 1 controllers but 
not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 
(2007) 81:12071–6. doi:10.1128/JVI.01261-07 
102. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, et al. 
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate 
of immune control. Blood (2009) 113:3978–89. doi:10.1182/blood-2008- 
10-182709 
103. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, 
et al. HIV controllers HLA-DRB1*13 and HLA-DQB1*06 have strong, poly-
functional mucosal CD4+ T-cell responses. J Virol (2010) 84(21):11020–9. 
doi:10.1128/JVI.00980-10 
104. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation 
of functionally distinct populations of virus-specific CD4 T  cells in HIV-
1-infected subjects with progressive disease: changes after antiretroviral 
therapy. Blood (2004) 103:966–72. doi:10.1182/blood-2003-04-1203 
105. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, et al. HLA 
class I restricted T-cell responses may contribute to the control of human 
immunodeficiency virus infection, but such responses are not always nec-
essary for long-term virus control. J Virol (2008) 82:5398–407. doi:10.1128/
JVI.02176-07 
106. Rosa DS, Ribeiro SP, Fonseca SG, Almeida RR, Santana VC, Apostólico 
Jde S, et  al. Multiple approaches for increasing the immunogenicity of 
an epitope-based anti-HIV vaccine. AIDS Res Hum Retroviruses (2015) 
31(11):1077–88. doi:10.1089/AID.2015.0101 
107. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, 
Drummond DD, et al. Effector memory T cell responses are associated with 
protection of rhesus monkeys from mucosal simian immunodeficiency virus 
challenge. Nat Med (2009) 15:293–9. doi:10.1038/nm.1935 
108. Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD. IL-12 selectively 
programs effector pathways that are stably expressed in human CD8+ 
effector memory T cells in vivo. Blood (2011) 118(14):3890–900. doi:10.1182/
blood-2011-05-357111 
109. Mussalem JS, Squaiella-Baptistão CC, Teixeira D, Yendo TM, Thies FG, 
Popi AF, et al. Adjuvant effect of killed Propionibacterium acnes on mouse 
peritoneal B-1 lymphocytes and their early phagocyte differentiation. PLoS 
One (2012) 7(3):e33955. doi:10.1371/journal.pone.0033955 
110. Longhini ALF, Mussalem JS, Takahashi H, Straus A, Longo-Maugéri IM. 
Soluble polysaccharide from Propionibacterium acnes with biological effects. 
Scand J Immunol (2001) 54(Suppl1):90. 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Teixeira, Ishimura, Apostólico, Viel, Passarelli, Cunha­Neto, 
Rosa and Longo­Maugéri. This is an open­access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, dis­
tribution or reproduction in other forums is permitted, provided the original 
author(s) and the copyright owner are credited and that the original publication 
in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
